NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis $0.31 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.30▼$0.3150-Day Range$0.26▼$0.3752-Week Range$0.25▼$6.79Volume616,357 shsAverage Volume1.92 million shsMarket Capitalization$18.75 millionP/E RatioN/ADividend YieldN/APrice Target$7.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Lyra Therapeutics alerts: Email Address Lyra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside2,216.3% Upside$7.13 Price TargetShort InterestBearish6.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.18) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.06 out of 5 starsMedical Sector396th out of 936 stocksSurgical & Medical Instruments Industry48th out of 101 stocks 4.0 Analyst's Opinion Consensus RatingLyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageLyra Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lyra Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.10% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently increased by 86.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYRA. Previous Next 1.8 News and Social Media Coverage News SentimentLyra Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lyra Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for LYRA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.42% of the stock of Lyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyra Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.18) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyra Therapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lyra Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About Lyra Therapeutics Stock (NASDAQ:LYRA)Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Read More LYRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYRA Stock News HeadlinesJuly 24 at 4:02 AM | americanbankingnews.comAnalysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $7.13July 19, 2024 | nz.finance.yahoo.comLyra Therapeutics, Inc. (LYRA) latest stock news & headlines – Yahoo FinanceJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.July 15, 2024 | insidermonkey.comLyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?May 29, 2024 | markets.businessinsider.comMaintaining Hold on ProKidney: Balancing Market Potential Against Clinical UncertaintiesMay 21, 2024 | msn.comLyra to cut 75% of workforce in portfolio shakeupMay 21, 2024 | globenewswire.comLyra Therapeutics Announces Cost-Cutting Measures to Preserve CapitalMay 15, 2024 | finance.yahoo.comTarget upgraded, CVS downgraded: Wall Street's top analyst callsJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.May 7, 2024 | markets.businessinsider.comHold Rating on Lyra Therapeutics Amid Clinical Trial Setbacks and Financial UncertaintiesMay 7, 2024 | msn.comBTIG Downgrades Lyra Therapeutics (LYRA)May 7, 2024 | markets.businessinsider.comWhere Lyra Therapeutics Stands With AnalystsMay 6, 2024 | msn.comWhy Lyra Therapeutics Stock Is Down 93% TodayMay 6, 2024 | markets.businessinsider.comLyra Therapeutics's Phase 3 Enlighten Trial 1 Fails To Meet Primary Endpoint; Stock DownMay 6, 2024 | marketwatch.comLyra Therapeutics Shares Plummet 90% After Chronic Rhinosinusitis Drug Fails in StudyMay 6, 2024 | investorplace.comWhy Is Lyra Therapeutics (LYRA) Stock Down 90% Today?May 6, 2024 | marketwatch.comLyra Therapeutics Lead Drug Candidate Fails in Phase 3 StudyMay 6, 2024 | globenewswire.comLyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisSee More Headlines Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LYRA CUSIPN/A CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees88Year FoundedN/APrice Target and Rating Average Stock Price Target$7.13 High Stock Price Target$15.00 Low Stock Price Target$0.50 Potential Upside/Downside+2,268.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,680,000.00 Net Margins-4,099.82% Pretax Margin-4,096.31% Return on Equity-77.34% Return on Assets-51.00% Debt Debt-to-Equity RatioN/A Current Ratio4.78 Quick Ratio4.78 Sales & Book Value Annual Sales$1.56 million Price / Sales11.76 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book0.19Miscellaneous Outstanding Shares60,970,000Free Float50,345,000Market Cap$18.34 million OptionableOptionable Beta-0.01 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Harlan W. Waksal M.D. (Age 71)Executive Chairman Comp: $210.06kDr. Maria Palasis Ph.D. (Age 59)CEO, President & Director Comp: $942.7kDr. John E. Bishop Ph.D. (Age 62)Chief Technology Officer Comp: $662.9kDr. Carmichael S. Roberts Jr. (Age 55)Ph.D., Co-Founder Mr. Jason Cavalier (Age 51)CFO, Treasurer & Secretary Comp: $464.11kMr. Ray KnoxVice President of OperationsMs. Ellen CavaleriSenior Vice President of Investor Relations & CommunicationsMr. Ronan P. O'Brien J.D. (Age 51)Chief Legal Officer Ms. Corinne Noyes (Age 56)Senior Vice President of Commercial Strategy & Market Development Comp: $426.73kMs. Vineeta Belanger Ph.D.Senior Vice President of Clinical AffairsMore ExecutivesKey CompetitorsPro-DexNASDAQ:PDEXSEP AcquisitionNASDAQ:SEPAInspireMDNYSE:NSPRNeuroneticsNASDAQ:STIMCytosorbentsNASDAQ:CTSOView All CompetitorsInsiders & InstitutionsRosalind Advisors Inc.Sold 109,751 shares on 7/12/2024Ownership: 1.697%Ikarian Capital LLCSold 197,555 shares on 5/17/2024Ownership: 1.733%Vanguard Group Inc.Bought 410,021 shares on 5/10/2024Ownership: 2.430%Harlan WaksalBought 25,000 shares on 11/10/2023Total: $74,000.00 ($2.96/share)View All Insider TransactionsView All Institutional Transactions LYRA Stock Analysis - Frequently Asked Questions How have LYRA shares performed this year? Lyra Therapeutics' stock was trading at $5.24 at the beginning of 2024. Since then, LYRA stock has decreased by 94.1% and is now trading at $0.3076. View the best growth stocks for 2024 here. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) posted its earnings results on Tuesday, April, 30th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.09. The firm earned $0.53 million during the quarter, compared to analysts' expectations of $0.40 million. Lyra Therapeutics had a negative net margin of 4,099.82% and a negative trailing twelve-month return on equity of 77.34%. When did Lyra Therapeutics IPO? Lyra Therapeutics (LYRA) raised $52 million in an initial public offering on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager. Who are Lyra Therapeutics' major shareholders? Lyra Therapeutics' top institutional investors include Rosalind Advisors Inc. (1.70%). Insiders that own company stock include Perceptive Advisors Llc, Nbvm Gp, Llc, Harlan Waksal, Edward T Anderson and C Ann Merrifield. View institutional ownership trends. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). This page (NASDAQ:LYRA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
